INTRODUCTION
Influenza virus (flu) still causes high morbidity and mortality in humans because of seasonal epidemics and global pandemics. The high mutation rate together with the genomic reassortment among different viral strains lead flu to elude vaccine-induced immunity and/or to develop resistance to the current antiviral drugs, which are limited to neuraminidase and M2 ion channel inhibitors. Therefore, the development of anti-flu therapeutics exploiting new targets and/or innovative strategies is highly desirable. To this end, the inhibition of one or more components of 
DESIGN OF cHTC ANALOGUES
In the first optimization study of hit compound 1, the attention was mainly focused on the C-2 position of the cHTC scaffold: different substituents replaced the o-fluorine atom, one or two methylene units were inserted between the C-2 phenyl ring and the core, and the phenyl ring was replaced by bulky aromatic rings or a cyclohexyl moiety. Fewer modifications involved the cycloheptane ring, whose size was reduced to cyclohexane or cyclopentane, and the C-3 pyridinyl carboxamide moiety, which was replaced by smaller groups such as primary amide, ethyl carboxylate, and carboxylic acid [18] . From this first set of compounds, clear SAR information emerged: the cycloheptane cannot be replaced by smaller rings and aromatic moieties both at C-2 and at C-3 position are required to impart potent activity.
By analyzing the predicted binding modes of the best PA-PB1 inhibitors reported so far in the PA cavity from X-ray crystal structure PDB ID 3CM8 [22] , it emerged that two hydrophobic interactions, one of which essential for the interaction with W706, seem sufficient to impart inhibitory activity against PA-PB1 interaction [14] . When additional hydrophobic interactions do not occur, favorable stabilization of the PA-small molecule interaction seems to take place with the formation of one (with Q408) or more favorable H-bonds.
By aligning some PA-PB1 inhibitors, we proposed a first pharmacophore model entailing two hydrophobic moieties separated by a "polar belt" with two H-bond acceptor points and two H-bond donor points [19] . More recently, we generated a new pharmacophore model by using all the best PA-PB1 inhibitors reported to date [14] . It preserves the two hydrophobic moieties, of which one involved in the interaction with W706. On the contrary, the two H-bond donor points do not seem critical for intermolecular interactions and only a H-bond acceptor point is preserved. Thus, two hydrophobic moieties and a central H-bond acceptor point appear to be the minimum structural requirement for PA-PB1 inhibition. However, since eight out of the eleven best PA-PB1 inhibitors studied matched two H-bond interaction points, additional H-bond interactions should be exploited to achieve a more efficient PA-PB1 inhibition.
Taking into account the indications coming from the previous SAR coupled with the recent computational suggestions, a new set of derivatives has been designed by inserting a hydroxyl group to the different positions of the C-2 phenyl ring (compounds 3-5, Table 1 ).
Computational studies based on the Fingerprints for Ligands and Proteins (FLAP) algorithm [23] were performed to analyze their binding poses in the PA cavity from the structure PDB ID 3CM8 [22] . To be consistent with our previous results [14] [15] [16] [18] [19] [20] , the FLAP software was used in the "Structure-based" mode: this approach allows to generate binding poses of a ligand in a protein cavity based on the similarity between their GRID fields [24] . Thus, although this approach is not a standard energy-based docking method, it proved to be successful in identifying or optimizing PA-PB1 inhibitors [15, [18] [19] [20] . Similarity scores were used to rank the most reliable poses for compounds 3-5 ( Fig. 2B-D) ; the FLAP binding pose previously obtained for hit compound 1 [18] was also reported as a reference in Fig. 2A . Compound 1 interacted with the first (defined by W706 and F411) and the second (defined by P710 and L666) hydrophobic pockets and with the additional central hydrophobic region (mainly generated by the aliphatic chain of E623 and the protein backbone). The similarity score for the proposed binding pose of 1 was 0.53. According to our model, the insertion of the hydroxyl group induced a significant change of the binding mode.
Indeed, the hydrophobic interaction with W706, already reported as a key residue for PA-PB1 inhibition [14] , still occurred for all compounds 1 and 3-5, even though the orientation of the cycloheptathiophene core in compounds 3-5 resulted to be inverted with respect to 1. As a consequence, the hydroxyl-substituted phenyl ring pointed towards a region of the PA cavity defined by F411, C415, and I621. Hydrophobic and H-bond interactions contributed to obtain a more favorable binding mode for compounds 3-5. Based on the FLAP similarity scoring, which takes into account a global estimation of hydrophobic, hydrophilic, H-bond donor and H-bond acceptor interactions, compounds 3-5 are almost equivalent (0.65, 0.63, and 065, respectively), with higher values with respect to compound 1 (0.53). Thus, the similarity scores are in agreement with the ELISA PA-PB1 interaction assay data, shown in Table 1 . A deeper visual inspection of the binding poses in Figure 2 was performed. The o-hydroxyl derivative 3 displayed the most efficient hydrophobic interactions between the cycloheptathiophene moiety with W706 and between the hydroxyphenyl group with the hydrophobic region defined by F411, C415, and I621 (Fig. 2B) . The latter hydrophobic region was recently described as another key area of PA for the interaction with potent inhibitors [25] . In addition, compound 3 resulted able to form a H-bond between I621 and its hydroxyl group, and a second one between the C-3 carbonyl group and Q408. On the contrary, the FLAP binding poses for the meta and para isomers 4 and 5 resulted shifted towards C415, weakening the hydrophobic interaction with W706 ( Fig. 2C-D) . This shift could allow 5 to form a new H-bond interaction between the p-hydroxyl group and the carbonyl group of C415, while the m-hydroxyl group was not involved in any specific interaction. Additional H-bonds with I621 and Q408 were still possible for both compounds 4 and 5. In agreement with the computational study, the biological evaluation of the three isomers (3, 4, and 5) showed that the hydroxyl group resulted useful to impart PA-PB1 interaction inhibitory activity especially when placed at ortho position (IC50 = 15 μM), and also allowed to achieve a really potent anti-flu activity (EC50 = 2.6 μM).
Given the potent antiviral profile of compound 3, the o-hydroxyphenyl moiety was maintained at the C-2 position while the C-3 position was thoroughly explored in a successive set of derivatives (compounds 6-16, Table 1 ). In particular, the 2-pyridinyl ring was replaced by a phenyl (6), pchlorophenyl (7), p-fluorophenyl (8) , and also by a thiazole (9) ring. A methylene unit was inserted between the aromatic ring and amide moiety at the C-3 position, as in compounds 10 and 11.
Aliphatic alkyl moieties, i.e. isopropyl, tert-butyl, cyclohexyl, piperazine, and 2-pyridilpiperazine (12) (13) (14) (15) (16) , were also used as C-3 substituents. Methoxy intermediates 17 [26] , 18, and 19 (Table 1) were also assayed to enrich the SAR. The replacement of the hydroxyl group at the C-2 phenyl ring was also investigated with the o-amino and p-amino derivatives 20 [26] and 21 [26] (Table 1) .
Finally, the C-2 and C-3 aromatic groups were interchanged synthesizing compounds 22 and 23 (Table 1) .
CHEMISTRY
The synthesis of the target compounds 3-9, 14, 18, 19, 22, and 23 was accomplished by applying the two-steps Gewald synthesis, as outlined in Scheme 1. Thus, the 2-cyano-N-(substituted)-acetamides 25 [27] , 26 [28] , 27, 28 [27] , and 29-31, prepared by reacting 3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropanenitrile 24 [27] with the appropriate amines in toluene, were used in a first Knoevenagel condensation with cycloheptanone. The successive cyclization step performed in the presence of sulfur and N,N-diethylamine in EtOH gave synthones 32 [18] , 33 [29] , and 34-38.
The reaction of synthones 32-38 with the appropriate acyl chlorides in dry pyridine led to the methoxyl derivatives 17 [26] [30] with the 2-methoxybenzoyl chloride in dry pyridine, to obtain derivative 47 that was then hydrolyzed under basic conditions. Coupling reaction of 3-carboxylic acid 48 with the appropriate alkyl amines in presence of benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and collidine in dry CH2Cl2 gave the desired 2-methoxybenzamido derivatives 49-54. Of note, the coupling reaction carried out in the same conditions but using anilines for the synthesis of the target compounds shown in Scheme 1, did not furnish the desired compounds but gave only the cyclized cyclohepta [4, 5] thieno [2,3- 
RESULTS AND DISCUSSION
The whole set of derivatives were first evaluated for the ability to inhibit the physical interaction between fluA PA and PB1 subunits by ELISA including the PB1(1-15)-Tat peptide [31] as a positive control of inhibition. In parallel, for all the synthesized compounds the antiviral activity was tested by plaque reduction assays (PRA) in Mardin-Darby canine kidney (MDCK) cells infected with a reference fluA virus, the A/PR/8/34 strain. Ribavirin (RBV), a known broad-spectrum inhibitor of RNA viruses polymerase [32] , was included as a positive control of inhibition. To exclude that the observed antiviral activities could be due to toxic effects on the target cells, all the synthesized compounds were also tested by MTT assays in MDCK cells. The antiviral activity and toxicity data for the tested compounds, as well as their ability to disrupt the PA-PB1 interaction in ELISA, are reported in Table 1 .
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Tat-PB11-15 peptide 35 ± 4 41 ± 5 >100
a Activity of the compounds in ELISA PA-PB1 interaction assays. The IC50 value represents the compound concentration that reduces by 50% the interaction between PA and PB1. b Activity of the compounds in plaque reduction assays with the flu A A/PR/8/34 strain. The EC50 value represents the compound concentration that inhibits 50% of plaque formation.
c Activity of the compounds in MTT assays. The CC50 value represents the compound concentration that causes a decrease of cell viability of 50%. All the reported values represent the means ± SD of data derived from at least three independent experiments in duplicate.
d Reported in reference [26] .
With the aim to exploit polar groups able to establish important H-bonds, the hydroxyl derivatives 
CONCLUSIONS
The continuous need to identify innovative anti-flu compounds led us to explore the subunits assembly of RdRp as a possible alternative antiviral target. This approach has already proven to be successful with the identification of effective PA-PB1 interaction inhibitors endowed with the ability to inhibit flu growth.
In this study we came back to the cHTC scaffold, which was functionalized with a hydroxyl moiety with the aim of exploiting additional H-bond interactions with key residues of the PA cavity, as suggested by recent computational studies [14] . As a result, new very interesting compounds were identified. In particular, C-2 o-hydroxyphenyl derivatives 3, 7, and 8 emerged as the best in inhibiting PA-PB1 interaction that well translated into a potent anti-flu activity. Two additional compounds, C-3 thiazole derivative 9 and C-2 p-aminophenyl compound 21, although showing a weaker ability to inhibit PA-PB1 interaction, were endowed with a very potent anti-flu activity (IC50 = 0.18 and 0.26 μM), reaching SI values >1388 and >961, respectively. For these compounds, further studies are in progress to uncover whether an additional mechanism of action might contribute to their potent anti-influenza activity.
Experimental section
Computational methods
The binding poses in the PA cavity were generated using the FLAP software in the structure-based mode (Molecular Discovery Ltd., UK; www.moldiscovery.com). The procedure has been extensively described elsewhere [16] . As in the previous studies, the main cavity of the crystallographic structure of a large C-terminal fragment of PA (aa 257-716) (pdb code: 3CM8)
[22] was used as a template. A total of 50 conformers for each ligand were generated to mimic the compound flexibility, and the most abundant protonation state of each molecule was used, as predicted by MoKa [33] . The probes used to generate the GRID Molecular Interaction Fields were
H (shape), DRY (hydrophobic interactions), N1 (H-bond donor) and O (H-bond acceptor)
interactions. The global similarity score (Glob-Pro) was used for ranking.
Chemistry
General experimental procedures
Commercially available starting materials, reagents, and solvents were used as supplied. All reactions were routinely checked by TLC on silica gel 60F254 (Merck) and visualized by using UV or iodine. Flash column chromatography was performed on Merck silica gel 60 (mesh 230-400).
After extraction, organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated The synthesis of some compounds reported in this study, i.e., 17 [26] , 20 [26] , 21 [26] , 24 [27] , 28
[27], 32 [18] , 33 [29] , and 46 [30] , has been previously described. Derivatives 34-36, 38, and 48 are commercially available but their synthesis has been not published before and is herein reported. The synthesis of compounds 27 [28] , 29 [34] , 30 [35] , and 31 [36] has been previously described but their preparation is herein reported through a different synthetic strategy.
General procedure for the preparation of 2-cyano-N-(substituted)acetamides 27 and 29-31
(Method A). To a solution of the appropriate amine (1.0 equiv) in toluene, 24 [27] (1.0 equiv) was added. The mixture was refluxed for 5 min, and then stirred at room temperature to obtain a precipitate, which was filtered, washed with Et2O, and dried. (27) . The tile compound was prepared starting from 
N-(4-Chlorophenyl)-2-cyanoacetamide
2-Cyano-N-(4-fluorophenyl)acetamide (29
2-Cyano-N-(thiazol-2-yl)acetamide (30
General procedure for the preparation of 2-amino-N-(substituted)-cycloheptathiophene-3-carboxamide synthones 34-38 (Method B)
. By applying a two-steps Gewald synthesis, a mixture of the appropriate 2-cyano-N-(substituted)acetamide (1.0 equiv), cycloheptanone (4.0 equiv), ammonium acetate (1.3 equiv), and glacial acetic acid (3.5 equiv) in benzene (10 ml/mmol) was heated at reflux for 16 h in a Dean-Stark apparatus. After cooling, the mixture was diluted with
CHCl3 and then washed with H2O, 10% NaCO3 solution, and finally H2O. The organic layer was concentrated to dryness to afford the crude Knoevenagel product, which was used directly in the successive step without further purification. Thus, to the crude Knoevenagel product (1.0 equiv) dissolved in EtOH, sulfur (4.0 equiv) and N,N-diethylamine (4.0 equiv) were added. The mixture was maintained at 40-50 °C for 2 h and then concentrated to dryness to yield a residue, which was treated with a mixture of cyclohexane/Et2O and filtered. 
2-Amino-N-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (34
N-(3-((2-Methoxyphenyl)carbamoyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)picolinamide (41).
The title compound was prepared starting from 33 [29] 
2-(2-Methoxybenzamido)-N-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (42
N-(4-Fluorophenyl)-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (43). The title compound was prepared starting from 36
through Method C and purified by treatment with Et2O, in 74% yield as light-brown solid. 1 
2-(2-Methoxybenzamido)-N-(thiazol-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (44).
The title compound was prepared starting from 37 through Method C and purified by flash chromatography eluting with cyclohexane:EtOAc 6:4, in 32% yield as yellow- solution of BBr3 in CH2Cl2 (6.0 equiv) was added dropwise maintaining the temperature at 0 °C.
N-Cyclohexyl-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (45
The reaction mixture was stirred at room temperature for 3-6 h and then quenched with MeOH and water. The organic solvent was removed under vacuum affording a residue, which was filtered and purified as described below.
2-(2-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (3).
The title compound was prepared starting from 17 [26] 
2-(3-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (4).
2-(4-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (5 
N-(4-Chlorophenyl)-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (7).
2-(2-Hydroxybenzamido)-N-(thiazol-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (9)
.
General procedure for C-3 amidation for derivatives 49-54 (Method E). To a solution of 48
(1.0 equiv) in dry CH2Cl2 was added the appropriate alkyl amine (3 equiv) followed by BOP (1.5 equiv) and finally collidine (4.0 equiv). The mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and successively washed with: water (twice), 0.5 M HCl, saturated NaHCO3 solution, water, and finally brine. The organic layer was dried over Na2SO4, filtered and then evaporated to dryness providing a residue that was purified as described below. 
2-Methoxy-N-(3-(4-methylpiperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)benzamide (53).
The title compound was prepared through Method E purified by flash chromatography eluting with CHCl3:MeOH 97:3, in 26% yield as white solid. 
2-Methoxy-N-(3-(4-(pyridin-2-yl)piperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)benzamide (54
Abbreviations:
Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, 
